David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1001
Accuray
ARAY
$31.8M
| $11.3M | 0.01% |
2,371,211
+355,715
| +18% | +$1.62M |
|
|
CLVS
1002
DELISTED
Clovis Oncology, Inc.
CLVS
| $11.3M | 0.01% |
454,879
+443,569
| +3,922% | +$11.1M |
|
1003
PUT
Comcast
CMCSA
$96.2B
| $11.3M | 0.01% |
281,500
-2,111,100
| -88% | -$79.4M |
|
|
AGEN
1004
Agenus
AGEN
$376M
| $11.2M | 0.01% |
192,824
+66,591
| +53% | +$4.13M |
|
1005
PUT
BP
BP
$110B
| $11.2M | 0.01% |
261,436
+146,806
| +128% | +$6.02M |
|
|
RHT
1006
CALL
DELISTED
Red Hat Inc
RHT
| $11.2M | 0.01% |
61,500
-23,600
| -28% | -$4.23M |
|
|
SAGE
1007
CALL
DELISTED
Sage Therapeutics
SAGE
| $11.2M | 0.01% |
70,300
-30,000
| -30% | -$4.34M |
|
1008
Estee Lauder
EL
$37.9B
| $11.1M | 0.01% |
67,260
-157,237
| -70% | -$23.1M |
|
|
GLUU
1009
DELISTED
Glu Mobile Inc.
GLUU
| $11.1M | 0.01% |
1,017,756
+53,400
| +6% | +$502K |
|
1010
CALL
Martin Marietta Materials
MLM
$37.8B
| $11.1M | 0.01% |
55,300
| – | – |
|
1011
Aclaris Therapeutics
ACRS
$963M
| $11.1M | 0.01% |
1,852,869
-425,495
| -19% | -$2.82M |
|
1012
Cannae Holdings
CNNE
$677M
| $11.1M | 0.01% |
456,964
-45,374
| -9% | -$954K |
|
1013
Travel + Leisure Co
TNL
$4.51B
| $11.1M | 0.01% |
273,177
-204,289
| -43% | -$8.6M |
|
1014
National Fuel Gas
NFG
$7.81B
| $11.1M | 0.01% |
181,422
-6,551
| -3% | -$380K |
|
1015
FirstEnergy
FE
$27B
| $11M | 0.01% |
265,008
-401,687
| -60% | -$16M |
|
|
TELL
1016
DELISTED
Tellurian Inc.
TELL
| $11M | 0.01% |
979,400
+286,659
| +41% | +$2.69M |
|
1017
Deckers Outdoor
DECK
$12.1B
| $10.9M | 0.01% |
446,982
-328,878
| -42% | -$7.47M |
|
|
TRUE
1018
DELISTED
TrueCar
TRUE
| $10.9M | 0.01% |
1,646,605
+305,383
| +23% | +$2.55M |
|
|
NEWR
1019
DELISTED
New Relic, Inc.
NEWR
| $10.9M | 0.01% |
110,776
-136,287
| -55% | -$13.5M |
|
|
EE
1020
DELISTED
El Paso Electric Company
EE
| $10.9M | 0.01% |
185,879
-82,231
| -31% | -$4.44M |
|
1021
APA Corp
APA
$14.5B
| $10.9M | 0.01% |
315,183
+217,994
| +224% | +$7.1M |
|
1022
Oneok
OKE
$57.8B
| $10.9M | 0.01% |
156,222
-929,783
| -86% | -$60.2M |
|
1023
BioCryst Pharmaceuticals
BCRX
$2.51B
| $10.9M | 0.01% |
1,338,695
-160,787
| -11% | -$1.38M |
|
|
FSCT
1024
DELISTED
ForeScout Technologies, Inc. Common Stock
FSCT
| $10.9M | 0.01% |
+259,377
| New | +$9.3M |
|
1025
Five Below
FIVE
$14.3B
| $10.9M | 0.01% |
87,486
+84,554
| +2,884% | +$10.2M |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.